STOCK TITAN

VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

VivoSim Labs (VIVS) signed a seven-figure testing agreement with a top-10 global pharmaceutical company. Work is underway on NAMkind liver and intestinal toxicology testing. VivoSim expects the agreement to push fiscal 2027 revenue growth above its 500%+ guidance, with contract revenue expected to be recognized in fiscal Q3 and Q4, ending December 31 and March 31, respectively.

Both toxicology businesses grew in the quarter ended September 30, 2026, with orders from large drugmakers and smaller biotech companies. VivoSim anticipates the customer will make NAMkind part of its routine preclinical testing after the program ends.

VivoSim also added testing to assess drug effects in liver and intestinal disease models and entered a collaboration with Chemveda Life Sciences to test compounds in human tissue models. The first programs are expected to begin this quarter.

Loading...
Loading translation...
5 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Fiscal 2027 revenue growth is expected to exceed VivoSim’s 500%+ guidance with the agreement
  • Major pointSeven-figure testing agreement with a top-10 global drugmaker covers liver and intestinal toxicology work already underway
  • Moderate pointLiver toxicology business grew in the quarter ended September 30, 2026
  • Moderate pointIntestinal toxicology business grew in the quarter ended September 30, 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.Routine preclinical testing with NAMkind is anticipated by VivoSim after the customer’s current program ends

Negative

  • None.

Key Figures

Agreement value: Seven-figure Fiscal 2027 revenue growth guidance: 500%+ growth Revenue recognition period: Fiscal Q3 and Q4 +5 more
Agreement value
Seven-figure
NAMkind testing services agreement with a top-10 global pharmaceutical company
Fiscal 2027 revenue growth guidance
500%+ growth
Company expects fiscal 2027 revenue to exceed this guidance
Revenue recognition period
Fiscal Q3 and Q4
Expected recognition; periods end Dec. 31 and March 31, respectively
Compounds in clinical dataset
92 small-molecule compounds
Dataset used to assess the NAMkind Liver model
Prediction accuracy
91%
NAMkind Liver model prediction of drug-induced liver injury
Sensitivity
90%
NAMkind Liver model
Specificity
95%
NAMkind Liver model
True liver toxicants detected
50% to 65%
Typical detection by animal models and traditional methods

Key Terms

new approach methodologies, drug-induced liver injury, specificity, pharmacodynamic
4 terms
new approach methodologies technical
"New Approach Methodologies (NAM) 3D human cellular models"
New approach methodologies are modern ways to evaluate the safety and effects of chemicals, drugs, and products using lab-grown cells, computer models, and fast automated tests instead of traditional animal studies. They matter to investors because these methods can speed up development, lower testing costs, reduce regulatory risk, and create business opportunities for companies that provide or use them—think of replacing slow road tests with a faster, cheaper simulator.
drug-induced liver injury medical
"predicted drug-induced liver injury with 91% accuracy"
Liver damage caused by a medication, vaccine, or supplement when the organ reacts badly to the substance; symptoms can range from mild enzyme changes to severe failure. Investors care because such reactions can stop clinical trials, force product recalls or label warnings, trigger regulatory scrutiny and lawsuits, and reduce future sales — like an engine overheating that forces a car off the road and halts its journey.
specificity technical
"with 91% accuracy, 90% sensitivity and 95% specificity"
Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.
pharmacodynamic medical
"with pharmacodynamic and target biomarker profiling"
Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Liver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind™ testing part of its regular flow of ongoing preclinical work

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety and efficacy testing, today announced a seven-figure agreement with a top-10 global pharmaceutical company (the “Customer”) for NAMkind™ testing services. With this agreement, the Company expects fiscal 2027 revenue to exceed the guidance of 500%+ growth it issued on July 15, 2026.

  • The agreement covers NAMkind™ liver and intestinal toxicology testing, with work already underway. Revenue under the agreement is expected to be recognized in VivoSim’s fiscal Q3 and Q4, ending Dec. 31 and March 31, respectively.
  • After this program, VivoSim anticipates that NAMkind™ testing will become part of the Customer's regular flow of ongoing preclinical work.
  • The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 12, shows growth in both its liver toxicology and intestinal toxicology businesses.
  • Growth came from both large pharma and smaller customers. Other current and future customers are also expected to move toward full integration of NAMkind™ testing into their workflows

How a Large Customer Adopts a New Test

A large pharmaceutical company (>$10B in annual revenue) does not quickly change how it tests drug candidates and requires extensive scientific due diligence to consider this kind of agreement. It then runs a new model on compounds whose clinical outcomes it already knows, compares the results with what its animal studies showed, and only then commits live program work. The agreement announced today covers that program work. Once it is complete, the Company anticipates that the Customer's compounds will come to VivoSim as the Customer's programs reach the relevant decision point, rather than as one-off studies.

“In July we told shareholders revenue would grow more than 500% this fiscal year. The quarterly report we filed last week shows both toxicology businesses growing, and this agreement on its own is expected to take us past that number,” said Keith Murphy, Executive Chairman of VivoSim Labs. “What matters more is what comes after it. A top-10 company has gone from evaluating our human liver and intestine models to paying for program work, and we expect its regular testing to follow. Other large customers are moving the same way.”

Since the Quarter Closed

On October 21, VivoSim added efficacy testing on disease models built from the liver and intestinal cells of patient donors, with pharmacodynamic and target biomarker profiling. On November 3, it entered a collaboration with Chemveda Life Sciences, which makes AI-designed compounds that VivoSim will then test in its human tissue models, with first programs expected to begin this quarter. This week, the Company's scientists are presenting new data demonstrating the practical impact on clinical derisking for clients of its multiparametric approach at the American College of Toxicology 47th Annual Meeting in San Antonio, Texas. The Company’s leadership is also meeting with current and prospective partners at the conference.

What Customers Are Buying

NAMkind™ liver and intestine models are built from primary human cells and dosed repeatedly over weeks. Across a clinical dataset of 92 small-molecule compounds, the NAMkind™ Liver model predicted drug-induced liver injury with 91% accuracy, 90% sensitivity and 95% specificity, whereas animal models and traditional methods typically detect 50% to 65% of true liver toxicants. Data presented at EUROTOX 2026 in September added further results in antibody-drug conjugates. Also in September, the U.S. Food and Drug Administration issued a direct final rule clarifying that non-animal methods may be used, where appropriate, to test the safety of drugs and biologics.

“Both toxicology service lines grew in the September quarter, with orders from large pharmaceutical companies and from smaller biotechs,” said Tony Lialin, Chief Commercial Officer of VivoSim Labs. “A large customer comes in through an evaluation, then a paid program, then its standing workflow. This Customer is at the second step, and we have others at the first.”

About VivoSim Labs

VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company's expectation that fiscal 2027 revenue will exceed its guidance of 500%+ growth; the timing and amount of revenue to be recognized under the agreement announced today; the Company's anticipation that NAMkind™ testing will become part of the Customer's regular flow of ongoing testing; the progress of other customers toward integration of NAMkind™ testing into their workflows; the Company's progress in marketing contract research services using NAMs models to pharmaceutical companies; the collaboration with Chemveda Life Sciences and the timing of its first programs; and the data presented at the American College of Toxicology 47th Annual Meeting. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on November 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.

Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does VivoSim Labs’ seven-figure testing agreement cover, and when will it recognize revenue?

The agreement covers NAMkind liver and intestinal toxicology testing for a top-10 global pharmaceutical company, and VivoSim expects to recognize the revenue in fiscal Q3 and Q4, ending December 31 and March 31, respectively.

What does the testing agreement mean for VivoSim Labs’ fiscal 2027 revenue guidance?

VivoSim expects the agreement to lift fiscal 2027 revenue growth above its prior guidance of 500%+ growth, which it issued on July 15, 2026.

Keep reading